ArticleWorld journal of surgical oncology2006
Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case.
Article in World journal of surgical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition.Alimentary pharmacology & therapeutics · 2018Trial
- Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).International journal of oncology · 2020Review
- Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma.Investigational new drugs · 2020Article
- Article
- Short-term treatment with taurolidine is associated with liver injury.BMC pharmacology & toxicology · 2017Article
- Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenograftsOncology letters · 2016Article
- Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.International journal of colorectal disease · 2014Article
- Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells.Genes & cancer · 2014Article
- Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).International journal of oncology · 2014Review
- Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.Journal of experimental & clinical cancer research : CR · 2013Article
- The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.BMC veterinary research · 2013Article
- Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.BMC cancer · 2010Article
- Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.Journal of carcinogenesis · 2010Article
- Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.Journal of experimental & clinical cancer research : CR · 2010Article
- Article
- TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.Journal of experimental & clinical cancer research : CR · 2008Article
- Treatment of multiple liver metastasis from gastric carcinoma.World journal of surgical oncology · 2007Article
- The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTaurolidine (TRD) is a novel agent with multimodal antineoplastic effects. We present the case of a tumor remission after intravenous administration of taurolidine in a patient with gastric cancer re-recurrence. CASE PRESENTATION: A 58 years old male patient suffering from a gastric adenocarcinoma was submitted to partial gastrectomy and partial liver resection (pT2, pN1, pM1L (liver segment 2), N0, V0). 24 months later a local recurrence was diagnosed and the patient was reoperated. Postoperatively the patient underwent a palliative chemotherapy with eloxatin, FU, and leucovorin. A subsequent CT-revealed a liver metastasis and a recurrence adjacent to the hepatic artery. After successful radiofrequency ablation of the liver metastasis the patient was intravenously treated with 2% taurolidine. The patient endured the therapy well and no toxicity was observed. CT-scans revealed a stable disease without a tumor progression or metastatic spread. After 39 cycles the patient was submitted to left nephrectomy due to primary urothelial carcinoma and died 2 days later due to myocardial infarction. Postmortem histology of the esophageal-jejunal anastomosis and liver revealed complete remission of the known metastasized gastric adenocarcinoma.
conclusionThe intravenous treatment with 2% taurolidine led to a histological remission of the tumor growth without any toxicity for the patient.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.